Description: Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.
Home Page: www.genprex.com
GNPX Technical Analysis
3300 Bee Cave Road
Austin,
TX
78746
United States
Phone:
877 774 4679
Officers
| Name | Title |
|---|---|
| Mr. John Rodney Varner | Co-Founder, Chairman, Pres & CEO |
| Mr. Ryan M. Confer M.S. | Chief Financial Officer |
| Ms. Catherine M. Vaczy Esq. | Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer |
| Dr. Hemant Kumar C.P.M., EMBA, Ph.D. | Chief Manufacturing & Technology Officer |
| Ms. Kalyn Dabbs | Sr. Mang. of Communications & Marketing |
| Mr. David M. Schloss | Sr. VP of HR |
| Mr. Thomas C. Gallagher Esq. | Sr. VP of Intellectual Property & Licensing |
| Dr. William E. Gannon Jr. | Member of Clinical Advisory Board & VP of Regulatory Affairs |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| Mr. Greg Jancarik C.M.A., CPA, M.B.A. | Corp. Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0266 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-03-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |